Qian Wei, Zhu Guopei, Wang Yulong, Wang Xiaoshen, Ji Qinghai, Wang Yu, Dou Shengjin
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai, 200032, China.
Med Oncol. 2014 Sep;31(9):178. doi: 10.1007/s12032-014-0178-2. Epub 2014 Aug 18.
The 5-year overall survival (OS) of loco-regionally advanced laryngeal and hypopharyngeal carcinoma (LA-LHC) has declined over the past two decades following the wide application of non-surgical approaches. We aimed to define the new role of open surgery combined with adjuvant chemoradiotherapy in the treatment of LA-LHC for improving survival while maintaining a functional larynx. In the current study, 90 LA-LHC patients treated with open surgery followed by postoperative RT/CRT in our institute from May 2005 to December 2012 were retrospectively analyzed. OS, disease-free survival (DFS), loco-regional failure-free survival (LRFFS) and distant metastasis-free survival (DMFS) were calculated, and prognostic factors were analyzed. Functional larynx preservation results were evaluated according to the head and neck quality of life (QoL) Scale. With a median follow-up period of 37 months, the 3- and 5-year OS, DFS, LRFFS and DMFS were 71.3, 63.7, 85.9, 73.7 and 55.9, 53.0, 81.6, 71.9 %, respectively. Vascular embolism and extracapsular extension (ECE) of the lymph nodes were prognostic factors for poorer OS (p = 0.045 and 0.046, respectively). Vascular embolism was the only prognostic factor for poorer DMFS (p = 0.005). Patients who underwent a conservative partial laryngectomy (CPL) experienced a higher QoL in the domains of speech, swallowing and emotion. Functional larynx preservation was achieved in 36/45 patients (80 %) who received CPL. The results of our study demonstrated that CPL followed by adequate adjuvant therapy could achieve superior oncological results compared with non-surgical approaches in LA-LHC patients while also maintaining satisfactory functional larynx in a majority of patients.
在过去二十年中,随着非手术方法的广泛应用,局部区域晚期喉癌和下咽癌(LA-LHC)的5年总生存率(OS)有所下降。我们旨在确定开放手术联合辅助放化疗在LA-LHC治疗中的新作用,以提高生存率,同时保留喉功能。在本研究中,我们回顾性分析了2005年5月至2012年12月期间在我院接受开放手术并术后接受放疗/同步放化疗的90例LA-LHC患者。计算总生存率(OS)、无病生存率(DFS)、局部区域无失败生存率(LRFFS)和远处转移无生存率(DMFS),并分析预后因素。根据头颈生活质量(QoL)量表评估喉功能保留结果。中位随访期为37个月,3年和5年的OS、DFS、LRFFS和DMFS分别为71.3%、63.7%、85.9%、73.7%和55.9%、53.0%、81.6%、71.9%。血管栓塞和淋巴结包膜外扩展(ECE)是OS较差的预后因素(分别为p = 0.045和0.046)。血管栓塞是DMFS较差的唯一预后因素(p = 0.005)。接受保守性部分喉切除术(CPL)的患者在言语、吞咽和情感方面的生活质量较高。45例接受CPL的患者中有36例(80%)实现了喉功能保留。我们的研究结果表明,与LA-LHC患者的非手术方法相比,CPL联合适当的辅助治疗可以取得更好的肿瘤学效果,同时在大多数患者中也能保持令人满意的喉功能。